Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal

Oct 22 2021

• By Alaric DeArment

Digital illustration of Cancer cell in colour background — Agenus said it would withdraw the BLA for its PD-1 inhibitor, balstilimab, in 2L cervical cancer • Source: Shutterstock

Related Content

PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review

Apr 24 2021

Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo

May 13 2021

Keytruda Cements Cervical Cancer Leadership With First-Line Nod

Oct 14 2021

Related Companies

Merck & Co., Inc.

Agenus Inc.

Roche Holding AG

Sanofi

Regeneron Pharmaceuticals, Inc.

GSK plc

Additional Topics

FDA ImmunoOncology Research & Development Cancer

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window